Revised forecast
Fiscal year ending September 2027 · Full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document.
The company aims to establish an earnings base and restore net sales and profitability through collaboration and cross-selling with 株式会社プリズム・メディカル, monetization of new businesses, expanded sales of Pix4D products, and the promotion of its medical tourism and wearable-related businesses.
Impairment loss: ¥349 thousand; loss on disposal of fixed assets: ¥3,120 thousand; contract cancellation loss: ¥770 thousand; litigation expenses: ¥10,000 thousand; settlement payment: ¥9,000 thousand; loss on valuation of investment securities: ¥9,999 thousand; total extraordinary losses: ¥33,240 thousand
| Item | Details |
|---|---|
| Net Sales | Not disclosed → ¥1,639 million（216.4%） |
| Operating profit | Not disclosed → ¥-124 million |
| Ordinary income | Not disclosed → ¥-226 million |
| Profit attributable to owners of the parent | Not disclosed → ¥-290 million |
| Net income per share | Not disclosed → -20.14 yen |
| Fiscal Period Covered | Fiscal year ending September 2027 |
| Period Covered | Full year |
| Previous-period results | Results for the fiscal year ended September 2026: net sales ¥518 million, operating loss ¥549 million, ordinary loss ¥735 million, net loss attributable to owners of the parent ¥622 million, net loss per share ¥43.15 |
| Reason for the revision | The company aims to establish an earnings base and restore net sales and profitability through collaboration and cross-selling with 株式会社プリズム・メディカル, monetization of new businesses, expanded sales of Pix4D products, and the promotion of its medical tourism and wearable-related businesses. |
| Details and amount of extraordinary loss | Impairment loss: ¥349 thousand; loss on disposal of fixed assets: ¥3,120 thousand; contract cancellation loss: ¥770 thousand; litigation expenses: ¥10,000 thousand; settlement payment: ¥9,000 thousand; loss on valuation of investment securities: ¥9,999 thousand; total extraordinary losses: ¥33,240 thousand |
| Dividend forecast revision | Forecast annual dividend for the fiscal year ending September 2027: ¥0.00 (no explicit amendment stated) |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Net sales declined in the fiscal year ended September 2026 because of the backlash from a large electronic medical record system-related project recorded in the previous fiscal year, while opportunities to win large projects of a similar scale were limited. For the fiscal year ending September 2027, the company plans to pursue collaboration and cross-selling with 株式会社プリズム・メディカル, monetize new businesses, and expand sales of Pix4D products.